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Perfusion Imaging*
Ami E. Iskandrian, MD,† Fadi G. Hage, MD‡
Birmingham, Alabama
Nuclear cardiology for detection of myocardial ischemia has
a long and proud history that spans many decades (1). As
currently used, stress myocardial perfusion imaging (MPI)
using single-photon emission computed tomography has
evolved over the years in its use of hardware, software,
radionuclides, acquisition protocols, processing algorithms,
interpretation methods, and stress modalities. The use has
also felt the impact of practice guidelines; appropriateness
criteria; radiation risk concerns; laboratory accreditation;
user certification; pre-authorization; declining reimburse-
ment; and the increasing use of positron emission tomog-
raphy and emergence of other imaging and nonimaging
modalities, such as computed tomography, stress echocar-
diography, stress magnetic resonance imaging; and frac-
tional flow reserve measurements. Those of us who have
been fortunate enough to witness the evolution remain
amazed by the value that MPI continue to provide to patient
care, albeit when used wisely.
See page 1054
Lessons learned from the application of MPI to clinical
care have been many. Of these, 3 have stood out as
significant over the years. The first involves the impact of
post-test referral bias on specificity of the test. Thus,
selective referral of patients with abnormal MPI to coronary
angiography artificially lowers specificity of MPI (2). Sec-
ond, coronary angiography should not be used as a “gold
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Astellas Pharma US, Inc.standard” for MPI, because anatomic coronary artery ste-
nosis is “neither a sufficient nor a necessary cause” for the
presence of myocardial ischemia (3). Third, MPI provides
prognostic information independent and complementary to
that obtained from anatomic modalities and/or risk factors
and has proven itself in numerous studies to be useful for
risk stratification in diverse populations (4). An important
consideration that is often overlooked links the last 2 points;
the variability in ischemic burden as it relates to coronary
anatomy is intimately associated with the independent
prognostic data provided by MPI.
In this issue of the Journal, Rozanski et al. (5) provide a
fourth important lesson: There has been a dramatic decline
in the frequency of myocardial ischemia detected by stress
MPI over the last 2 decades (Fig. 1). This observation is
based on data derived from stress MPI performed on 39,515
patients at a single institution (after excluding 12,174
patients with prior myocardial infarction [MI], coronary
revascularization, cardiomyopathy, or valvular heart dis-
ease). The sheer number of studies performed at 1 center is in
itself remarkable and a testimony to the widespread adoption
of this imaging modality by the community. The importance
of this observation is further emphasized by the expertise of
this group. Therefore, it is worthwhile to examine the reasons
behind this decline and future implications.
There has been a progressive decline in cardiovascular
deaths in the United States since the 1970s. From 1998 to
2008, the rate of death attributable to cardiovascular disease
declined 30.6% (6). Reflecting these changes, the annual
cardiac event rates in contemporary trials in which partici-
pants were on optimal medical therapy such as the DIAD
(Detection of Ischemia in Asymptomatic Diabetics) study
(0.6% cardiac death/MI) (7), the WOMEN (What Is the
Optimal Method for Ischemia Evaluation in Women) study
(8) (1.1% coronary death/hospitalization for acute coronary
syndrome or heart failure), COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive Drug
Evaluation) trial (4.1% death/MI) (9), and BARI 2D
(Bypass Angioplasty Revascularization Investigation 2 Di-
abetes) study (4.7% death/MI/stroke) (10) were low. A large
proportion of this welcome decline in event rates has been
attributed to modern medical therapy and control of risk
factors (11). Thus, the observed decrease in ischemia de-
tected by Rozanski et al. (5) could also be a reflection of this
trend. In COURAGE (12), medical therapy and coronary
revascularization were associated with significant decrease in
ischemia detection by imaging. Reduction in ischemia has been
reported with common antianginal medications, ranolazine
and statins (13). This salutatory effect observed even after
short-term therapy is independent of changes in large-vessel
coronary artery stenosis severity and is yet another reason why
coronary angiography is a not a reliable reflection of myocardial
perfusion pattern. It is provocative to suggest that more
aggressive medical therapy results in less ischemia, which in
turn is associated with better outcomes.
d
p
c
i
f
m
t
i
o
o
p
a
n
t
s
1067JACC Vol. 61, No. 10, 2013 Iskandrian and Hage
March 12, 2013:1066–8 Frequency of Ischemia Detection Using MPIAnother aspect of this decline has to do with the change
in MPI referral patterns. With the introduction of numer-
ous guidelines and especially appropriateness criteria (first in
2005 and then in 2009) (14) that limit indications for MPI
referral, and growing concerns over radiation exposure with
MPI, one would expect detection of more and not less
ischemia. This is reflected in the decreasing proportion of
MPI performed in asymptomatic individuals in the current
study. Similarly, the increase in proportion of patients with
diabetes and obesity would again have predicted a higher
incidence of ischemia. Other changes in patient character-
istics such as decreasing age, smoking, and lower blood
pressure are consistent with the observed decline in ische-
mia. In propensity-matched analysis that controlled for
these changes, the temporal decline in ischemia persisted.
Another form of change in referral pattern has to do with
the source of the referral. It is possible that early on, this
academic imaging center had a broad catchment area. Over
the years, with MPI becoming more office-based and more
available in the community, patients with high likelihoods
of disease were shifted to outpatient/office centers, whereas
referrals from noncardiologists who are less likely to have
significant disease became over-represented in hospital-
based academic centers. Changing patterns of resource
utilization is another potential explanation for this trend. It
is possible that individuals with high pre-likelihood ratios
for coronary disease (and abnormal perfusion) are triaged to
other noninvasive imaging tests or directly to angiography
in more recent years. Data that address these concerns are
not provided, but there is no reason to suspect such trends
explain these findings, as nationwide there is still concern
that far too many invasive angiograms show no significant
Figure 1 Frequency of Abnormal Perfusion and
Annual Mortality
The frequency of abnormal perfusion (defined as summed stress score involv-
ing more than 5% of the left ventricle) and annual mortality rates on stress
myocardial perfusion imaging shown for 4 successive time periods. Data, used
with permission, from Rozanski et al. (5).coronary disease (15).During the duration of this study, we have witnessed a
change in stress modalities. Over these 2 decades, pharmaco-
logic stress (mostly vasodilator) increased from less than one-
third in the first epoch to more than one-half in the last. It is
unlikely that this shift is behind the declining rate of abnormal
perfusion. First, the increase in myocardial blood flow is more
robust with vasodilators than with exercise, and vasodilator
MPI should be at least as sensitive for detecting ischemia as
exercise MPI is. Second, prevalence of abnormal perfusion was
higher among patients undergoing pharmacologic MPI versus
exercise MPI in this study. In fact, pharmacologic (vs. exercise)
MPI was independently associated with an abnormal MPI in
all 4 epochs with increasing odds ratio (for 2006 to 2009: 2.63,
p 0.001). Also, the decline in abnormal MPI was at least as
ramatic (if not more so) in the exercise subgroup versus the
harmacologic subgroup.
Finally, as pointed out earlier, MPI has been constantly
hanging over time. It is certainly possible that a change in
nterpretation threshold for an abnormal MPI is responsible
or the decline in ischemia detection due to technical advance-
ents in hardware, software, and imaging protocols even
hough the interpretation was done by same readers. It is
nteresting that most of the decline for abnormal perfusion
ccurred in the first decade with little decline after 2001 (Fig.
1 in Rozanski et al. [5]). Another interesting observation is that
mortality rates although declined during the same period did so
at a much slower rate (Fig. 1). The ratio of abnormal
perfusion/annual mortality was 9.8:1 in the first period and
3.6:1 in the last (Table 1 in Rozanski et al. [5]). Because
utcomes are provided for the overall population and not by
erfusion pattern, it is difficult to interpret these findings. Our
nalysis of the data shows that if risk of death for patients with
ormal MPI remained constant over time, then risk of death in
hose with abnormal MPI has more than doubled even in the
etting of decreasing overall risk (Fig. 2, scenario A). Alterna-
Figure 2 Risk Stratification With
Myocardial Perfusion Imaging
A hypothetical example to explain the discrepancy in the rates of decline of
myocardial ischemia detected by myocardial perfusion imaging and annual mor-
tality between the 1991 to 1995 and 2006 to 2009 epochs. We assume here
an arbitrary 1% annual mortality rate for patients with normal perfusion in the
1991 to 1995 epoch. See text for details.
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Frequency of Ischemia Detection Using MPI March 12, 2013:1066–8tively, relative risk for abnormal/normal MPI could have
remained constant over time if risk of both normal and
abnormal MPI has increased (Fig. 2, scenario B). The first
ossibility is compatible with better risk stratification using
PI in the current era, whereas the second is compatible
ith changing referral patterns. The more likely possibility
s that these trends reflect a combination of these 2
cenarios. Obviously, in the absence of data, this analysis is
urely speculative.
The implications of this study could be far-reaching if
hey are true nationwide. The registry planned by the
merican Society of Nuclear Cardiology could provide this
uch-needed data. What lies in the balance is defining a
opulation for which MPI is still cost-effective if the rate of
etected abnormalities is low and decreasing. For example,
n this study, the frequency of ischemia in patients without
ypical angina referred for exercise MPI and who achieved
arget heart rate in the contemporary cohort was very low. It
ay arguably be more effective to perform exercise treadmill
esting on these patients without MPI as an initial test. A
ecent study by Bourque et al. (16) showed that patients
ho have high exercise capacity with no ischemic ST-
egment changes are very unlikely to have ischemia on MPI.
uch an approach will be useful only in the subset of
atients suitable for exercise stress, an ever-shrinking pro-
ortion of patients. We have recently introduced a novel
oncept that may help in better risk-stratifying patients with
ormal perfusion by vasodilator MPI (17). Another impli-
ation is that it may become increasingly difficult to recruit
atients for clinical trials, whether they involve new
maging agents, stress agents, or evaluation of the impact
f treatment (drug, device, revascularization, gene ther-
py, or treatment strategy) on ischemia reduction. The
arge National Heart, Lung, and Blood Institute–sponsored
SCHEMIA (International Study of Comparative Health
ffectiveness With Medical and Invasive Approaches) trial
ill be a good test for this new hurdle as it will specifically
arget subjects with moderate-to-large areas of ischemia.
We are grateful to Rozanski et al. (5) for this contribu-
ion, as we were 3 decades ago to their other seminal
ontribution of declining specificity due to referral bias and
heir introduction of the term normalcy rate (2).
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